The European Food Safety Authority (EFSA) aims to sharpen the focus on antimicrobial resistance (AMR) surveillance with its latest manual guiding the 2025 data reporting under Directive 2003/99/EC and Commission Implementing Decision (EU) 2020/1729. This development will certainly engage public health officials, food producers, veterinary sectors, and regulatory bodies, who will all face new protocols and reporting expectations that could trigger resource reallocations and operational shifts.
This technical report, published on January 27, 2026, by EFSA, provides detailed instructions and specifications for the submission of AMR data, responding to the growing global concern over resistant pathogens that impact both human and animal health. As a specialized agency under the EU umbrella, EFSA's guidance plays a pivotal role in shaping how AMR is monitored across member states.
Serving as a technical manual rather than binding legislation, the document contains mandatory requirements derived from existing regulatory frameworks but clarifies and standardizes reporting criteria to enhance data quality and comparability. It outlines concrete requirements for data formats, pathogens to be included, sampling strategies, and timelines — setting measurable standards without proposing new policy goals or budget allocations.
By reinforcing standardization and stringent reporting practices, EFSA prioritizes transparency and scientific robustness, implicitly endorsing enhanced EU-level oversight of AMR surveillance. This potentially increases regulatory burden for national authorities and food industry players required to align their monitoring systems but promises better coordinated responses to AMR risks across the EU.
Stakeholders stand to experience a mix of outcomes: regulators and public health entities benefit from improved data clarity facilitating policy decisions; food producers and veterinary sectors may face increased compliance costs and operational adjustments; civil society and consumers could gain from strengthened public health safeguards; however, the added administrative workload might draw scrutiny from economically pressed industry groups.
Looking ahead, EFSA’s manual sets an essential groundwork for the next cycle of AMR-related data collection and monitoring, likely prompting reactions and adaptations from Member States’ competent authorities and possibly informing future legislative refinement by the European Commission and Parliament.